-
1.发明授权Use of inhibitors of scinderin and/or ephrin-A1 for treating tumors 失效使用scinderin和/或ephrin-A1抑制剂治疗肿瘤公开(公告)号：US08058252B2
公开(公告)日：2011-11-15
申请号：US12159460
申请日：2006-12-28
CPC分类号： C12N15/1135 , A61K31/7105 , A61K31/711 , C12N15/113 , C12N15/1136 , C12N2310/14
摘要： The invention relates to the use of inhibitors of the expression or the activity of scinderin and/or of ephrin-A1 inhibitors for increasing the susceptibility of tumor cells to CTL killing. Such inhibitors may be for instance interfering RNAs targeting the scinderin gene and/or interfering RNAs targeting the ephrin-A1 gene.
摘要翻译： 本发明涉及使用scinderin和/或ephrin-A1抑制剂的表达或活性的抑制剂来增加肿瘤细胞对CTL杀伤的敏感性。 这样的抑制剂可以是例如靶向靶向ephrin-A1基因的scinderin基因和/或干扰RNA的干扰RNA。
-
2.发明授权Mutated peptide compounds, derived from hsp70, useful in cancer immunotherapy 失效衍生自hsp70的突变肽化合物，可用于癌症免疫治疗公开(公告)号：US06855802B1
公开(公告)日：2005-02-15
申请号：US09673795
申请日：1999-04-22
申请人： Frédéric Triebel , Catherine Gaudin
发明人： Frédéric Triebel , Catherine Gaudin
IPC分类号： G01N33/53 , A61K31/711 , A61K38/00 , A61K39/00 , A61K39/395 , A61K48/00 , A61P35/00 , A61P43/00 , C07K14/47 , C07K16/18 , C12N5/10 , C12N15/09 , C12N15/12 , C12P21/08 , C12Q1/68 , G01N33/574 , A01N37/18
CPC分类号： C07K14/47 , A61K39/00 , A61K2039/5154 , A61K2039/53 , C12N2510/00
摘要： The invention concerns a method for identifying peptide compounds derived from hsp70, having at least one mutation relative to the hsp70 natural sequence, said compounds bringing about a response T specific of tumours, and the peptide compounds obtainable by said method. The invention also concerns the use of said peptide compounds for performing repeated immunization in a subject so as to interrupt immune tolerance for the corresponding natural (non-mutated) peptide. Said peptide compounds are useful for preparing a medicine designed in particular for treating cancer optionally in combination with any agent provoking tumour cell stress.
摘要翻译： 本发明涉及用于鉴定源自hsp70的肽化合物的方法，其相对于hsp70天然序列具有至少一个突变，所述化合物引起肿瘤特异性的T反应，以及可通过所述方法获得的肽化合物。 本发明还涉及所述肽化合物在受试者中进行重复免疫以便中断相应天然（非突变）肽的免疫耐受的用途。 所述肽化合物可用于制备特别用于治疗癌症的药物，任选地与任何引起肿瘤细胞应激的药物组合。
-
公开(公告)号：US08674172B2
公开(公告)日：2014-03-18
申请号：US13264479
申请日：2010-04-12
CPC分类号： G01N33/5011 , C12N5/0693 , C12N2503/02
摘要： The present invention relates to a prostate cancer cell line CNCM deposit number I-4126, the use thereof for preparing resistant prostate cancer cell lines, the resistant prostate cancer cell lines, and the use of these prostate cancer cell lines for screening compounds of interest.
摘要翻译： 本发明涉及前列腺癌细胞系CNCM保藏号I-4126，其用于制备抗性前列腺癌细胞系，抗性前列腺癌细胞系以及这些前列腺癌细胞系用于筛选目的化合物的用途。
-
公开(公告)号：US20120036587A1
公开(公告)日：2012-02-09
申请号：US13264479
申请日：2010-04-12
CPC分类号： G01N33/5011 , C12N5/0693 , C12N2503/02
摘要： The present invention relates to a prostate cancer cell line CNCM deposit number I-4126, the use thereof for preparing resistant prostate cancer cell lines, the resistant prostate cancer cell lines, and the use of these prostate cancer cell lines for screening compounds of interest.
摘要翻译： 本发明涉及前列腺癌细胞系CNCM保藏号I-4126，其用于制备抗性前列腺癌细胞系，抗性前列腺癌细胞系以及这些前列腺癌细胞系用于筛选目的化合物的用途。
-
-
-
搜索结果
4 条记录 (耗时 0.018 秒)
